收费全文 | 98911篇 |
免费 | 8900篇 |
国内免费 | 4776篇 |
耳鼻咽喉 | 736篇 |
儿科学 | 2122篇 |
妇产科学 | 1656篇 |
基础医学 | 11447篇 |
口腔科学 | 2180篇 |
临床医学 | 9824篇 |
内科学 | 16287篇 |
皮肤病学 | 1449篇 |
神经病学 | 7715篇 |
特种医学 | 1899篇 |
外国民族医学 | 31篇 |
外科学 | 8051篇 |
综合类 | 16677篇 |
现状与发展 | 13篇 |
预防医学 | 8584篇 |
眼科学 | 2894篇 |
药学 | 9339篇 |
30篇 | |
中国医学 | 3482篇 |
肿瘤学 | 8171篇 |
2024年 | 268篇 |
2023年 | 1221篇 |
2022年 | 2703篇 |
2021年 | 3540篇 |
2020年 | 3179篇 |
2019年 | 2916篇 |
2018年 | 2888篇 |
2017年 | 3286篇 |
2016年 | 3563篇 |
2015年 | 3497篇 |
2014年 | 6200篇 |
2013年 | 6821篇 |
2012年 | 6356篇 |
2011年 | 7023篇 |
2010年 | 5902篇 |
2009年 | 5521篇 |
2008年 | 5749篇 |
2007年 | 5741篇 |
2006年 | 5166篇 |
2005年 | 4594篇 |
2004年 | 3887篇 |
2003年 | 3352篇 |
2002年 | 2783篇 |
2001年 | 2397篇 |
2000年 | 2021篇 |
1999年 | 1748篇 |
1998年 | 1501篇 |
1997年 | 1280篇 |
1996年 | 1148篇 |
1995年 | 1040篇 |
1994年 | 846篇 |
1993年 | 663篇 |
1992年 | 584篇 |
1991年 | 445篇 |
1990年 | 416篇 |
1989年 | 320篇 |
1988年 | 253篇 |
1987年 | 205篇 |
1986年 | 173篇 |
1985年 | 272篇 |
1984年 | 225篇 |
1983年 | 138篇 |
1982年 | 194篇 |
1981年 | 120篇 |
1980年 | 126篇 |
1979年 | 84篇 |
1978年 | 49篇 |
1977年 | 42篇 |
1976年 | 32篇 |
1975年 | 26篇 |
Objective
To assay peripheral inter-ictal cytokine serum levels and possible relations with non-invasive vagus nerve stimulation (nVNS) responsiveness in migraineurs.Methods
This double-blinded, sham-controlled study enrolled 48 subjects and measured headache severity, frequency [headache days/month, number of total and mild/moderate/severe classified attacks/month], functional state [sleep, mood, body weight, migraine-associated disability] and serum levels of inflammatory markers [inter-ictal] using enzyme-linked immunoassays at baseline and after 2 months of adjunctive nVNS compared to sham stimulation and suitably matched controls.Results
No significant differences were observed at baseline and after 2 months for headache severity, total attacks/month, headache days/month and functional outcome [sleep, mood, disability] between verum and sham nVNS. However, the number of severe attacks/month significantly decreased in the verum nVNS group and circulating pro-inflammatory IL-1β was elevated significantly in the sham group compared to nVNS. Levels of anti-inflammatory IL-10 were significantly higher at baseline in both groups compared to healthy controls, but not at 2 months follow-up [p?<?0.05]. Concentrations of high-mobility group box-1 (HMGB-1), IL-6, tumor-necrosis factor-α (TNF-α), leptin, adiponectin, ghrelin remained unchanged [p?>?0.05]. No severe device-/stimulation-related adverse events occurred.Conclusion
2 months of adjunctive cervical nVNS significantly declined the number of severe attacks/month. Pro-inflammatory IL-1β plasma levels [inter-ictal] were higher in sham-treated migraine patients compared to verum nVNS. However, pro- [IL-6, HMGB-1, TNF-α, leptin] and anti-inflammatory [IL-10, adiponectin, ghrelin] mediators did not differ statistically. Profiling of neuroinflammatory circuits in migraine to predict nVNS responsiveness remains an experimental approach, which may be biased by pre-analytic variables warranting large-scale biobank-based systematic investigations [omics]. 相似文献Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use.
Results: The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (>96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF.
Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. 相似文献